Work

Mapping Two Decades of KRAS-Targeted Drug Development in Cancer: A Bibliometric Analysis of Scientific Evolution and Emerging Therapeutic Trends

Year: 2026
Type: article
Abstract: Aim To characterize the global research landscape, collaboration patterns, intellectual structure, and emerging hotspots of KRAS-targeted therapy in cancer using bibliometric methods. Methods Web of Science Core Collection records from 1991 to 2026 were retrieved with a validated search (benchmark recall 25/25) and analyzed after restriction to articles and reviews. Bibliometrix, VOSviewer, and R were used to evaluate annual output, citations, country and institutional activity, journal quartiles, international collaboration, source distribution, author productivity, co-occurrence networks, co-citation structure, co-authorship, and trend topics. Results The final dataset included 4599 publications, comprising 3926 articles and 673 reviews, across 868 sources and 104,438 cited references. Annual output increased gradually through the 2010s and accelerated after 2020, rising by 85% to its highest level in 2025. Country-affiliation occurrence frequency was highest for the USA and China, while country-level citation impact was led by the USA; US papers appeared more often in first-quartile journals (66.6% vs. 51.2%) and were more often internationally co-authored (26.9% vs. 15.5%), whereas China’s first-quartile share rose from 40.4% before 2016 to 55.1% in 2021–2026. Major sources included Cancer Research, Cancers, Oncogene, Clinical Cancer Research, and Oncotarget. Trend-topic and co-occurrence analyses showed a shift from farnesyltransferase inhibition and anti-EGFR biomarker research toward KRAS G12C, sotorasib, efficacy, acquired resistance, and KRAS G12D. Conclusion KRAS-targeted therapy research has evolved from a pathway-centered and indirect-targeting literature, through a biomarker-dominated period, into a rapidly expanding precision-oncology field whose growth followed clinical validation of direct inhibition. Current bibliometric patterns highlight direct mutant KRAS inhibition, resistance biology, and allele-specific targeting beyond G12C as major research frontiers, with pancreatic cancer translation and international collaboration as priorities. These findings should be interpreted as indicators of research activity and intellectual structure rather than evidence of therapeutic efficacy.
Language: English
Open Access status: hybrid
Estimated APC paid: $4,090
OpenAlex ID: W7167889574
FWCI:
Cites: 34
Cited by:
Related to: 10